Physician profile
Dipal Patel
NPI 1477562338
$3,901.19
in general payments reported to CMS, 2019-2025
29 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $288 · 2021: $417 · 2022: $704 · 2023: $837 · 2024: $771 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $463.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $442.54 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Boston Scientific Corporation | $333.68 | 2021-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Esperion Therapeutics, INC. | $302.05 | 2020-2024 | Nexletol |
| Cvrx, INC. | $248.21 | 2022-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $244.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.79 | 2020-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.13 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.72 | 2019-2025 | Lifevest |
| Amgen INC. | $164.96 | 2019-2024 | Repatha |
| Abbott Laboratories | $147.26 | 2022-2025 | Navitor, Mitraclip |
| Novo Nordisk INC | $134.81 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $129.69 | 2019-2022 | |
| Amarin Pharma, INC. | $110.46 | 2020-2021 | |
| Bridgebio Pharma, INC. | $89.88 | 2025 | Attruby |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $76.43 | 2025 | Onpattro |
| Pfizer INC. | $75.86 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $59.91 | 2023-2024 | Inpefa |
| W. L. Gore & Associates, INC. | $55.90 | 2022 | |
| Medtronic, INC. | $33.72 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $30.53 | 2019-2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $28.36 | 2024 | Arcalyst |
| Silk Road Medical, INC. | $27.41 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Scpharmaceuticals INC. | $21.63 | 2025 | |
| Abiomed | $20.74 | 2024 | Impella |
| Ucb, INC. | $20.13 | 2021 | |
| Edwards Lifesciences Corporation | $19.58 | 2023 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $18.65 | 2022 | |
| Dexcom, INC. | $15.84 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.